Navigation Links
Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
Date:5/24/2011

PALO ALTO, Calif. and AUCKLAND, New Zealand, May 24, 2011 /PRNewswire/ -- Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella exclusive rights to CEN-209, a novel investigational drug designed to enhance the effectiveness of radiotherapy and chemotherapy when treating solid tumors that are hypoxic—or oxygen-starved—and therefore resistant to standard forms of radiotherapy and chemotherapy.

CEN-209 is selectively activated in areas of low oxygen often found within solid tumors.  These areas develop within tumors due to their rapid growth, which impairs the blood vessels bringing nutrients and oxygen, resulting in hypoxia.  

"Hypoxic tumors are generally resistant to radiotherapy and to chemotherapy, and there is no effective treatment for such tumors today," says Thorsten Melcher, PhD, President of Centella Therapeutics.  "Hypoxia occurs in most types of solid tumors, but not necessarily in every patient with a given tumor type. For example, in lung cancer patients, roughly 50 percent of tumors have hypoxic regions.(1)  In the future, successful treatment of hypoxic tumors will likely require identifying affected patients and giving them a hypoxia-specific drug, like CEN-209, in addition to standard treatment."(2)

Radiotherapy works by damaging tumor cells' DNA, but only in well-oxygenated areas, whereas CEN-209 is designed to 'switch on' and damage the DNA only of hypoxic cells, leaving other cells alone," Melcher adds.  "Thus, the two treatment approaches have the potential to complement each other, and CEN-209 is specifically designed to be preferentially used in combination with radiotherapy."

Professor William Wilson and Associate Profes
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... 2011 Aoxing Pharmaceutical (NYSE Amex: ... focusing on research, development, manufacturing and distribution of ... subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, ... Intellectual Property Office of The People,s Republic of ...
... 2011 IRIDEX Corporation (Nasdaq: IRIX ) ... had issued to IRIDEX a patent applying to a ... ophthalmic surgical procedures. The patent, No. 7,909,816 and titled ... consumable medical devices already in the IRIDEX product line ...
Cached Medicine Technology:Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 2Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 3IRIDEX Granted U.S. Patent for Stepped Angled Laser Handpieces Used in Eye Surgery 2IRIDEX Granted U.S. Patent for Stepped Angled Laser Handpieces Used in Eye Surgery 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... Viejo, California (PRWEB) December 25, 2014 ... release of ProFire 5k. A fully customizable business presentation ... . , “Adding the ProFire 5k business tool, users ... Said Christina Austin, CEO of Pixel Film Studios. “ProFire ... look and style to add professionalism to a presentation” ...
(Date:12/24/2014)... Wi (PRWEB) December 25, 2014 AlignLife ... are unable to afford certain items. During the holiday season, ... "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner ... and staff such joy, knowing that we are able to ... present had it not been for the generosity of our ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and ... under $150 . All these items are brand new; they ... already been updated with the new range of high quality ... far. All iFitDress.com’s designs are made according to the latest ... materials. Every outfit from the company is handpicked by skilled ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The ... that allege the blood thinner caused life-threatening episodes ... a leadership structure for the proceeding, Bernstein Liebhard ... 17th, the Court plans to select lawyers to ... also plans on appointing a Plaintiffs’ Steering Committee, ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
... who live in poverty and who have abused their children ... emotional support. A new study has found that mothers ... abuse and neglect were able to reduce how much they ... children after a series of home visits from therapists who ...
... research has shown that listening to music alleviates anxiety and ... spatial awareness. However, until now, research has not addressed how ... still the same if we listen to music whilst performing ... preference for a particular type of music affect performance? A ...
... HealthDay Reporter , TUESDAY, July 27 (HealthDay News) -- Worried ... Seeking out the right Web site might help, a new study ... to a specially designed Internet site for weight maintenance were better ... people who logged on less often, new research finds. ...
... Amanda Gardner HealthDay Reporter , MONDAY, July 26 ... power of the sniff to help severely disabled people play ... in wheelchairs. The experimental "sniff controller" takes advantage of ... not damaged and are still able to send messages to ...
... NY) For the third time in four months, the ... National Institutes of Health (NIH) has awarded Albert Einstein College ... helping people infected with multidrug-resistant tuberculosis (MDR-TB). Taken ... latest awardee Neel Gandhi, M.D. , assistant professor ...
... found that patients often exhibit a significant decrease in weight and ... (arthroplasty). The study is the first of its type to ... Americans between the ages of 29 to 73 years. The ... total of 196 Mount Sinai patients who had knee or hip ...
Cached Medicine News:Health News:Abusive mothers improve parenting after in-home training, emotional support of therapists 2Health News:Abusive mothers improve parenting after in-home training, emotional support of therapists 3Health News:Background music can impair performance, cites new study 2Health News:To Help Keep Weight Off, Turn to the Web 2Health News:To Help Keep Weight Off, Turn to the Web 3Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 2Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 3Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Many knee and hip replacement patients experience weight decrease after surgery 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: